KRAS and colorectal carcinoma: Among the CRC stages, stage III patients with KRAS mutation exhibited a lower 3-year OS (71.9% mutation (+) vs. 89.4% mutation (−), p = 0.02, number of patients: 41 vs. 71) and DFS (54.0% mutation (+) vs. 73.5% mutation (−), p = 0.022, number of patients: 31 vs. 59) rates (Figure 5).